Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors

NCT04774952 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT04774952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04774952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 7, 2021
Completion date
June 28, 2024
Enrollment
58 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors